Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma

Molecule-targeted therapy, such as sorafenib, is one of the effectively therapeutic options for advanced hepatocellular carcinoma (HCC). However, acquired resistance to sorafenib has been found in some HCC patients, resulting in poor prognosis. It is reported that PD-L1 and DNA methyltransferases (D...

Full description

Saved in:
Bibliographic Details
Published in:Oncol Rep
Main Authors: Liu, Jianhua, Liu, Yahui, Meng, Lingyu, Liu, Kai, Ji, Bai
Format: Artigo
Language:Inglês
Published: D.A. Spandidos 2017
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5561980/
https://ncbi.nlm.nih.gov/pubmed/28627705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2017.5722
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items